Sources Say Amgen Plans To Sell Biotech Japanese Unit (Japan)
This article was originally published in PharmAsia News
Executive SummaryThe world's largest biotechnology company, Amgen plans cost reductions, beginning by closing its Japan unit, according to sources. U.S.-based Amgen is suffering a decline in sales and is asking $403 million for its Tokyo operation, beginning the talks with Japanese drugmakers. A spokeswoman called the reports "speculation." The Japan unit develops biotech treatments for asthma, cancer and rheumatoid arthritis in Japan. (Click here for more
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.